Skip to main content

Post-Kidney Transplant Adverse Outcomes Increased With BMI-BSA Obesity

Medically reviewed by Carmen Pope, BPharm. Last updated on May 27, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, May 27, 2025 -- Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes, according to a study published online May 21 in Transplantation Direct.

Roxaneh Zaminpeyma, from Dalhousie University in Halifax, Nova Scotia, Canada, and colleagues examined post-KT adverse outcomes associated with obesity, defined using combined BMI-BSA parameters, in a cohort of adult KT recipients across the United States.

A total of 242,432 patients were included in the final study: 32.0 and 28.6 percent had obesity based on BMI and BSA, respectively. The researchers found that the adjusted risk for death-censored graft loss, all-cause graft loss, and delayed graft function was greatest when both BMI and BSA indicated obesity compared with nonobese BMI and BSA (adjusted hazard ratios, 1.23, 1.09, and 1.58, respectively); the risk was significantly greater than when BMI and BSA were discordant.

"Patients with discordance between obesity-defined BMI and BSA are at significantly lower risk than those categorized as obese by both BMI and BSA metrics," the authors write. "Combined BMI-BSA-defined obesity should be considered when defining obesity-related risk at the time of kidney transplantation."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death

WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related...

Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss

FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...

In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity

TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.